Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA 2-093 adjunctive therapy for refractory partial seizures
2004-000766-12Phase 3Completed
- Sponsor
- BIAL
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine in epilepsy (4 arms), sponsored by BIAL. Primary endpoint: Primary efficacy endpoint. Started Feb 2005; status: completed.
02
Drugs
eslicarbazepine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2004-000766-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000766-12.